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Objective: To expand the spectrum of genetic causes of autosomal recessive cerebellar ataxia (ARCA).
Case report: Two brothers are described who developed progressive cerebellar ataxia at 3 1/2 and 18 years,
respectively. After ruling out known common genetic causes of ARCA, analysis of blood peroxisomal markers
strongly suggested a peroxisomal biogenesis disorder. Sequencing of candidate PEX genes revealed a homozygous
c.865_866insA mutation in the PEX2 gene leading to a frameshift 17 codons upstream of the stop codon. PEX gene
mutations usually result in a severe neurological phenotype (Zellweger spectrum disorders).
Conclusions: Genetic screening of PEX2 and other PEX genes involved in peroxisomal biogenesis is warranted in
children and adults with ARCA.
Background
Main causes of autosomal recessive cerebellar ataxia
(ARCA) include Friedreich ataxia, ataxia telangiectasia
and oculomotor apraxia type 1 and 2 [1,2]. Cerebellar
ataxia may sometimes be the leading neurologic symp-
tom in a limited number of autosomal recessive meta-
bolic diseases [1,2] but has not been reported as such in
inherited peroxisomal diseases due to isolated enzyme
deficiency or peroxisomal biogenesis defect [3,4].
Patients with adrenomyeloneuropathy, the adult form of
X-adrenoleukodystrophy, or adult Refsum disease
(resulting from mutations in PHYH gene coding for the
peroxisomal phytanoyl-CoA hydroxylase enzyme, or in
PEX7 gene coding for the peroxin 7 receptor protein)
often develop cerebellar ataxia but have always asso-
ciated neurological symptoms (peripheral neuropathy,
retinitis pigmentosa, spastic paraplegia) [5,6]. Patients
with peroxisomal biogenesis defects (Zellweger spectrum
disorders) may also display cerebellar dysfunction
among many other neurological symptoms when they
have prolonged survival [3,4]. Peroxisomal biogenesis
disorders (PBDs) are characterized by the loss of multi-
ple peroxisomal metabolic functions caused by mutation
in 13 PEX genes involved in the import of peroxisomal
matrix proteins [3,4]. Except for rhizomelic chondrodys-
plasia punctata due to mutations in the PEX7 gene, all
patients have multiple metabolic impairments involving:
(1) oxidation of very long chain fatty acids (VLCFA),
branched-chain fatty acids (phytanic and pristanic acids,
bile acid intermediates) and L-pipecolic acid; (2) and
plasmalogen biosynthesis. We report two brothers who
developed isolated progressive cerebellar ataxia at 3 1/2
and 18 years. After ruling out common genetic causes
of ARCA, screening of peroxisomal metabolites revealed
in the youngest brother at 9 years a moderate increase
in the plasma levels of phytanic and pristanic acids sug-
gesting PBD. This patient was afterwards found to have
a homozygous mutation in the PEX2 gene. His older
brother carrying the same PEX2 gene mutation devel-
oped cerebellar ataxia at 18 years.
Case presentation
The younger brother (P1) was evaluated for progressive
g a i td i s t u r b a n c ea tt h ea g eo f9y e a r s .H ew a st h ef o u r t h
child of non-consanguineous healthy parents. His mile-
stones were normal but mild dysarthria was noticed at
2 1/2 years. Gait disturbance appeared at 3 1/2 years. At
7 years, he walked with a wide-based gait but was able to
run, rise from the floor and climb stairs. On neurological
examination, the child had moderate truncal ataxia, dys-
arthria but no tremor and pyramidal signs in the lower
limbs. Symptoms worsened at the age of 9 years: he was
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out support and had difficulties with writing. On the
Wechsler Intelligence Scale for Children (WISC-III), his
full, verbal and performance IQ were 75, 84 and 79. He
had truncal ataxia, moderate cerebellar tremor, mild
scanning dysarthria, nystagmus, slow saccades without
oculo-motor apraxia and hyporeflexia. His total ataxia
score evaluated by the International Cooperative Ataxia
Rating Scale (ICARS) was 17/100. He had no other neu-
rological symptoms and his physical examination was
normal. Cerebellar ataxia exacerbated slowly up to the
age of 14 years but he was still able to walk without sup-
port. The ICARS score was 33/100. No other neurologi-
cal signs were present and cognitive function remained
normal.
At the age of 9 years, a brain MRI showed atrophy of
the vermis and lateral hemispheres of the cerebellum
that worsened at the age of 14 years, but without signs
of demyelination or neuronal migration defects in fore-
brain and cerebellum (Figure 1). Fundoscopic examina-
tion, electroretinogram, EEG, electromyography,
peripheral nerve conduction, visual, brainstem auditory
and somatosensory evoked potentials, and audiogram
were normal at 9 and 14 years. Other normal tests
included ECG, cardiac ultrasound, liver enzymes, ammo-
nia, lactate, vitamin E, lipid electrophoresis, alpha-foeto
protein, plasma and urinary amino acids and urinary
organic acids. Molecular studies of frataxin and apra-
taxin genes ruled out Friedrich ataxia and cerebellar
ataxia with oculomotor apraxia 1 (AOA1).
His older brother (P2) had normal neurologic exami-
nation at 14 years, but at the age of 18 years he started
to develop cerebellar signs with impaired gait, dysmetria,
ataxia of the trunk, dysarthria, hyporeflexia and slow
saccades with oculomotor apraxia. The ICARS score
was 17/100. He had no other neurological symptoms.
On the WISC-IV, his full, verbal and performance IQ
were 80, 74 and 75 (normal range). Brain MRI showed
isolated cerebellar atrophy at 18 years (Figure 1). Elec-
troretinogram, peripheral nerve conduction, visual,
brainstem auditory, and somatosensory evoked poten-
tials were normal. These two patients had a 7-year-old
brother and two sisters, aged of 22 and 25 years, who
had a normal neurologic examination.
After ruling out Friedrich ataxia, AOA1 and common
metabolic causes of cerebellar ataxia, peroxisomal para-
meters were analysed in plasma of patient P1 and his
brother and sisters. Plasma VLCFAs were nearly normal
in patients P1 and P2, but a moderate increase in the
levels of phytanic and pristanic acids was found, prompt-
ing us to suspect a peroxisomal disorder (Table 1).
Further studies showed a moderate increase of bile acid
intermediates (DHCA and THCA) in plasma and normal
levels of pipecolic acid in plasma and CSF (Table 1).
The findings of a moderate elevation of pristanic and
phytanic acids with normal VLCFAs in plasma from P1
and P2 suggested initially that they might suffer from
a-methylacyl-CoA racemase (AMACR) deficiency [7].
This was ruled out by the measurement of R- and S-
isomers of DHCA and THCA in plasma and AMACR
activity in fibroblasts from P1. The presence of DHCA and
THCA traces also excluded the diagnosis of adult Refsum
disease. Further metabolic studies performed in fibroblasts
[ 7 , 8 ]f r o mP 1s h o w e dn o r m a lp lasmalogen biosynthesis,
DHAP-AT activity, oxidation of VLCFAs, and pristanic
acid (Table 2). Oxidation of phytanic acid was only slightly
abnormal. Taken together, those analyses pointed towards
a mild peroxisomal defect, but did not clearly indicate at
which level. Since few patients with PEX2, PEX10 and
PEX12 gene mutations display a relatively mild PBD phe-
notype, a complete genomic sequencing of these genes
was performed. No mutations were identified in the
PEX10 and PEX12 gene, but an apparent homozygous
c.865_866insA mutation was found in the PEX2 gene in
patients P1 and P2. The mother was heterozygous for the
c.865_866insA mutation. Paternal genotype could not be
determined because the proband’s father had lost contact
with the family. No mutation was found in P1 and P2
asymptomatic siblings, who had normal peroxisomal para-
meters in plasma and no neurologic symptoms.
Discussion
The PEX2, PEX10 and PEX12 genes encode peroxins
that are integral peroxisomal membrane proteins with a
Figure 1 Brain T-1 weighted magnetic resonance imaging
showing marked cerebellar atrophy in P1 at the age of 9 years
(panel A) and 14 years (panel B), and in P2 at the age of
18 years (panel C). Panel D shows a normal brain MRI in a
16 years-old control.
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as ubiquitin ligases required for the ubiquitination of
the PTS1-receptor (PEX5) in the peroxisomal membrane
[9].
We do not have any reliable background data on the
frequency of the c.865_866insA mutation in the pro-
band’s ethnic background, and this mutation has not
b e e nr e p o r t e di nt h ed a t a b a s et h a tw eh a v ec o n s u l t e d
(http://www.hgmd.cf.ac.uk; http://www.dbpex.org;
http://www.ncbi.nlm.nih.gov/snp). However, because
the c.865_866insA mutation introduces a frameshift 17
codons upstream of the stop codon, resulting in a PEX2
protein with an altered C-terminus (p.Ser289LysfsX36),
it is very unlikely that it could be a non-pathogenic var-
iation occurring in the normal population. Additionally,
homozygosity for this mutation co-segregated undeni-
ably with the disease in the family. It should be noted,
however, that homozygosity for this mutation could not
be confirmed due to the unavailability of paternal DNA.
This leaves the possibility that the paternal mutant allele
harbors a different mutation, for example a (partial)
deletion of the PEX2 gene, which will not be recognized
when in trans with the c.855_866insA allele. In that
case the c.855_866insA allele will also appear as
homozygous.
The fact that peroxisomes in the patient’sf i b r o b l a s t s
were normally present and contained catalase suggests
that the mutated PEX2 is localized correctly in the per-
oxisomal membrane and still is partly active. How this
moderate impairment in peroxisome biogenesis impairs
selectively neuronal cells in cerebellum is unknown. It is
possible that environmental factors and modifier genes
contribute to the different age of onset of clinical symp-
toms in the two affected brothers.
Table 1 Analysis of plasma VLCFAs, branched-chain fatty acids and bile acids intermediates
Controls (5% - 95% range) Patient 1 Patient 2
▪ VLCFAs
- C22:0 40-119 34 36
- C24:0 33-84 33 38
- C26:0 0.45-1.32 0.76 0.95
- C24:0/C22:0 0.57-0.92 0.98 1.07
- C26:0/C22:0 0-0.02 0.02 0.03
▪ Branched-chain fatty acids
- Phytanic acid 0-9 23.5 10.3
- Pristanic acid 0-4 27.9 16.7
- Pristanic/Phytanic ratio 0.05-0.4 1.19 1.62
▪ Bile acids intermediates
- DHCA 0-0.02 0.4 0.1
- THCA 0-0.08 0.1 0.2
All values are given in μM.
Table 2 Biochemical abnormalities in fibroblasts from patient 1 and 5 other patients with PEX2 mutations




- C26:0 1214-1508 1296 186 1172 98 78 215
- Pristanic acid 675-1121 1114 2 495 41 1 23
▪ Phytanic acid alpha-oxidation
a 39-97 28 5 ND 2 1 15
▪ Plasmalogen de novo synthesis
- %pPE in PE 72.8-81.4 79.6 58.5 0.8 17.4 10.4 35.4
- %pPC in PC 3.3-5.5 5.8 1.1 0.5 2.8 1.3 4.2
▪ DHAPAT-activity
b 5.8-12.3 8.3 0.7 7.8 0.6 1.3 `0.8
▪ Catalase immunofluorescence + + - +/- - - -
▪ Immunoblot analysis
- Acyl-CoA oxidase (70/50/20 kDa) +/+/+ +/+/+ +/-/- +/+/+ +/-/- +/-/- +/-/-
- Peroxisomal thiolase (44/41 kDa) +/+ +/+ +/- +/- +/- +/- +/-
Patients 1-4 are described in ref 12. Patient 5 is a newly identified PEX2 patient with severe clinical phenotype.
apmol/(h.mg protein);
bnmol/(2 h.mg protein).
List of abbreviations: DHAP-AT, dihydroxyacetonephosphate-acyltransferase; DHCA, dihydroxycholestanoic acid; PC, total phosphatidylcholine; pPC, plasmalogen
phosphatidylcholine; PE, total phosphatidylethanolamine; pPE, plasmalogen phosphatidylethanolamine; THCA, trihydroxycholestanoic acid; VLCFA, very-long chain
fatty acids.
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pattern, abnormal Purkinje cell dendritic arborization) are
observed in PEX 2 deficient mice [10]. Tissue-selective
elimination of peroxisomes in the mouse’s brain or liver
suggests that the folial abnormalities may be due mainly to
the lack of hepatic peroxisomes, whereas the Purkinje cells
defects may imply both brain and liver peroxisomal abnor-
mal metabolism [11]. The patients that we describe seem
to have progressive cerebellar atrophy rather than malfor-
mative cerebellar hypoplasia.
The clinical phenotype of these two patients strongly
differs from PBD patients with PEX2 gene mutations who
may display cerebellar symptoms in addition to other
severe neurological signs in the context of Zellweger
spectrum disorders [12,13].
While this work was in progress, PBD patients with
mild phenotypes including cerebellar ataxia were shown
to have mutations in PEX10 gene or PEX16 gene [14,15].
However, these patients displayed additional neurological
symptoms including axonal motor neuropathy and
decreased vibration sense in PEX10- mutated patients
and spastic paraparesia, leukodystrophy peripheral neu-
ropathy and cataracts in patients with PEX16 mutation.
In contrast, our patients have a milder phenotype
restricted to isolated cerebellar ataxia.
Conclusion
These clinical observations broaden the spectrum of
phenotypes associated with PEX gene mutations but,
most importantly, indicate that a search for PEX gene
defect must be considered as potential cause of ARCA.
Systematic screening for such PEX gene defect can
easily and reliably be performed by the simple measure-
ment of peroxisomal metabolites in plasma and will
probably increase the frequency of PBD patients with
mild phenotypes such as ARCA.
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